Biocon and Mylan tie-up with Fujifilm to market Adalimumab biosimilar in EU

Biocon and its partner Mylan ink an in-licensing agreement with Fujifilm Kyowa Kirin Biologics (FKB) to expedite commercialization of Adalimumab biosimilar.

Europe being a major market for the generic version of mega-blockbuster drug Humira, the Mylan and Biocon have roped in FKB to accelerate the go-to-market process for adalimumab biosimilar there. The product developed by FKB's is in advance review stage and is expected to obtain approval in the second half of 2018 in Europe.

Biocon retains its financial interest in line with its global collaboration with Mylan for monoclonal antibodies.

Humira (adalimumab) is a mega-blockbuster drug owned by AbbVie. It has been targeted by many biosimilars that are under review or in late stage development for the European and American markets. Humira is used alone or in combination to reduce chronic inflammatory conditions (signs and symptoms) for people suffering from auto immune disorders like rheumatoid arthritis and psoriasis.

Meanwhile, at 14:50 hours on Thursday, Biocon was trading at Rs. 622.00 per share up by 1.44 per cent on the BSE.